New HIV-vaccine tested on people

February 13, 2012 in HIV & AIDS

Scientists from the Antwerp Institute of Tropical Medicine, Antwerp University Hospital and Antwerp University have tested a new 'therapeutic vaccine' against HIV on volunteers. The participants were so to say vaccinated with their own cells. The researchers filtered certain white blood cells out of the volunteer's blood, 'loaded' them outside the body and then gave them back. The immune system of the testees was better than before in attacking and suppressing the virus, the scientists reported in the top journal AIDS. But they still cannot cure the disease.

Actually, medical science can control an HIV-infection quite well, with a medicine cocktail. 'Seropositive' people (people who are infected with the ) now can lead a reasonably normal life, but their is not exterminated. When they stop the treatment it immediately rebounds.

Science knows what the problem is: the 'special forces' in our blood (the CD8 , in medical lingo) get not enough support from the general staff (the dendritic cells, that show the combat units what to attack). Dendritic cells exhibit on their exterior typical parts of the virus to be attacked. But human dendritic cells are not that good in getting the right information on the HIV virus and to transform it into good examples for the CD8 battle cells.

The virologists and HIV-physicians of the Institute of and the haematologists of Antwerp University Hospital have cooperated for years on that problem. Together they succeeded to 'load' dendritic cells of seropositive volunteers in the lab with the building instructions ( in the form of so-called ) for HIV proteins. They could make the dendritic cells to execute the instructions and to exhibit the resulting typical part of the HIV virus on their surface. Subsequent research in test tubes demonstrated that the 'loaded' dendritic cells were able to activate battle cells.

Time had come to proceed to humans. Flemish, Belgian and French research foundations provided grants. Six seropositive persons who for a long time already used the drug cocktails, were prepared to volunteer. The scientists filtered the dendritic cells from a large volume of their blood, cultivated them in test tubes in the cell-therapy unit of the Antwerp University Hospital and provided them with the genetic instructions of an HIV virus. They then froze the loaded cells.

The volunteers received four times, with four-week intervals, a small quantity of their own reworked dendritic cells. And indeed, after each vaccination the CD8 battle cells in their bodies recognised the virus better and better, while the vaccination had virtually no side effects. The most important result was that the vaccine-activated battle cells became better and better in suppressing the virus, in test tubes for the moment. But HIV remains a disguise artist; it still succeeds in changing its proteins sufficiently fast and often to let at least a few viruses escape the attack.

So it remains impossible to cure AIDS, but the results are encouraging: the vaccine, made of the participant's own dendritic cells, is safe and has some therapeutic effect, be it a limited one. But sufficiently strong for a publication in the most renowned journal for researchers, AIDS. And more than sufficient to enthuse and motivate the Antwerp scientists.

Provided by Institute of Tropical Medicine Antwerp

4 /5 (4 votes)  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

chthonic
Feb 13, 2012

Rank: not rated yet
Channeling my inner Cub Scout, I smiled when I read about the testees.
Rank 4 /5 (4 votes)
Related Stories
Relevant PhysicsForums posts

More news stories

After a decade, global AIDS program looks ahead

(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...

HIV & AIDS created 5 hours ago | popularity not rated yet | comments 0

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

HIV & AIDS created May 19, 2013 | popularity 5 / 5 (1) | comments 0

AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

HIV & AIDS created May 18, 2013 | popularity 5 / 5 (2) | comments 0

Peer-referral programs can increase HIV-testing in emergency departments

Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...

HIV & AIDS created May 17, 2013 | popularity not rated yet | comments 0

HIV no barrier to getting liver transplant, study finds

(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.

HIV & AIDS created May 17, 2013 | popularity not rated yet | comments 0


Study shows where scene context happens in our brain

In a remote fishing community in Venezuela, a lone fisherman sits on a cliff overlooking the southern Caribbean Sea. This man –– the lookout –– is responsible for directing his comrades on the water, ...

Monoclonal antibody appears effective and safe in asthma Phase IIa trial

A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.

New rice contamination reported in China

Authorities are investigating rice mills in southern China following tests that found almost half of the staple grain in one of the country's largest cities was contaminated with a toxic metal.

New tumour-killer shows great promise in suppressing cancers

Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.

Exercise levels may predict hospitalizations in COPD population

Clinical measurement of physical activity appears to be an independent predictor of whether or not patients with chronic obstructive pulmonary disease (COPD) will end up being hospitalized, according to a new study conducted ...

Delayed transfer to the ICU increases risk of death in hospital patients

Delayed transfer to the intensive care unit (ICU) in hospitalized patients significantly increases the risk of dying in the hospital, according to a new study from researchers in Chicago.